Message from the founder, at the occasion of the release of the novel Pneumotox and Cardiotox websites and Apps. August 2026

Dear colleagues, dear friends, dear Pneumotox and Cardiotox users,

I transferred the chairmanship of my Division, to retire but only partly, still joyfully practicing as a consulting hospital-based pulmonary physician near Dijon (Eastern France).

During the past decade, an ever increasing but heterogenous body of literature on drug-induced respiratory and cardiac toxicity has emerged. This literature was surveyed daily and evaluated for causality daily, as it has been by Pneumotox for over three decades now. For instance, 5,400 new references were added to the bibliography section of Pneumotox since 2013. Pneumotox always was updated as needed (total updates = 870).

Large pharmacovigilance databases have shed some light on DIRD in real life. AI may emerge as a significant servant and contributor in the daily approach of this topic.

Beside surveying the literature, steering Pneumotox was a daily and multifaceted challenge. Since Pneumotox was built to be free for all, funding was and remains a challenge. A ‘Wish to Donate” link is now and for the first time present on the frontpage. No least were technological issues and advancements in computer and web science, requiring Pneumotox to be extensively overhauled to a new, more stable and secured environment. Short of being upgraded or rebuilt, websites can get vulnerable. As you noticed, technological obsolescence led to the shutdown of both Pneumotox and Cardiolox Apps (Apologies for that). The eagerly awaited new Apps have been carefully rebuilt and rejuvenated. They will be back on track shortly at your fingertips.

Thank to a team of talented people at Akyos Communication in Dijon, Pneumotox data and files were retrieved, compiled, synched, merged and secured in a safe backup that is updated and saved daily. Pneumotox and Cardiotox websites had their graphic redesigned while staying inspired by the previous version, a sort of ‘soft transition’. Previous features were maintained as new ones were added and others are being developed.

As a safeguard, the previous version of Pneumotox (2.2) is conserved, maintained and secured as a safe background resource. The physical literatre of the ‘good ole days’ and pdfs files are appropprately stored.

I will invite distinguished colleagues to join me in an International Pneumotox Monitoring and Scientific Board, to ensure the maintenance, development, progress and funding of iatrogenic science.

Should you need, I encourage you to contact me, wishing Pneumotox will meet your expectations in terms of quality, reliability, updated state, and hopefully excellence in the foreseable future. As ever prior, Pneumotox will stay ad-free and independent. I will continue surveying the literature carefully, answering personally any query including rechallenge data when available 7/365 for as long as possible. Until new hands possibly take over.

Thank you very much for your trust. My warmest regards.

Philippe Camus MD